Immunotherapy demonstrates long-term success in treating lymphoma

Featured In: Cell Biology

By EurekAlert Friday, October 30, 2024

Loading...

(WASHINGTON - October 30, 2024) – Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). This study was pre-published online today in Blood, the official journal of the American Society of Hematology.

Lymphoma is a cancer of white blood cells called lymphocytes that are largely responsible for maintaining the body's immunity, and EBV is one of the most common human viruses that can have a long-lasting impact on the body's immune system. Immune-compromised patients who receive HSCT, especially from mismatched donors or matched but unrelated donors, may be at higher risk of developing EBV-lymphoma than other patients. Previous studies have suggested that EBV-lymphoma occurs most often in the first few months post-transplant.

The researchers hypothesized that aggressive EBV-lymphomas may be responsive to control or eradication with EBV-specific cytotoxic T lymphocyte (CTL) treatment. (CTLs are highly specialized white blood cells that build the body's defenses against disease.) To test their theory, the team infused EBV-specific CTL lines into two groups of patients: those who were undergoing HSCT and were at high risk of developing EBV-lymphoma, and patients who had already developed lymphoma. The study reported that CTL treatment successfully prevented the development of EBV-lymphoma in all 101 patients in the at-risk group who received the therapy prophylactically and achieved sustained complete remission in 11 of the 13 patients (85 percent) treated therapeutically (those who already had the disease).

"Therapy with EBV-specific CTLs was effective for these severely immunocompromised patients. The CTLs successfully reached tumors, multiplied, and were able to kill the tumor cells," said lead study author Helen Heslop, MD, of the Center for Cell and Gene Therapy at Baylor College of Medicine, The Methodist Hospital, and Texas Children's Hospital.

While the successful outcomes result from a number of factors in the study, the researchers attribute some of the success of the trial to the time of treatment. The CTL lines were infused soon after stem cell transplantation, when the existing white blood cell count was still low and was not quickly regenerating, allowing the infused cells to more quickly multiply and mediate anti-viral and anti-tumor effects. In addition, by marking and tracking the CTL genes, the team was able to demonstrate that the cells could survive for up to nine years in the body, conferring long-term protection.

With strong clinical outcomes, the study team is working to determine the most appropriate role and timing for CTL infusions. Some newer therapies (such as monoclonal antibodies) offer prophylactic and therapeutic options but cannot offer long-term protection. Therefore, treatment with CTLs may be reserved for the highest risk patients – those with a diagnosis of immune deficiency or a history of EBV-lymphoma, or those who develop elevated EBV levels after therapy with monoclonal antibodies.

Importantly, the study found that this type of therapy is not only effective, but economically advantageous. A preliminary analysis showed that a patient-specific CTL line can be manufactured, tested, and infused for approximately $6,000, a cost that compares well with other modalities used in the treatment of EBV-lymphoma. Moreover, the team determined that it is possible to manufacture cells in one location and ship them to another center for infusion, with reproducible and consistent results and clinical outcomes.

"It's important to note that this promising therapy is not only effective, but it is also a cost-effective option for high-risk patients," said Dr. Heslop.

SOURCE

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Meeting the Challenges of Long-term Time-lapse Imaging

Oct 26

Recent technological developments in the sequence capture of cellular events through a light microscope can be combined to image multiple independent experiments automatically, with many advantages.

Handle With Care

Aug 26

Researchers face the dual challenges of difficult to handle and hard to maintain stem cells.

Six Tips for More Successful Cell Cultures

Aug 18

For those who perform cell culture experiments, it pays to be meticulous. Even seemingly minor handling techniques and lab equipment features can make a difference in achieving success.

Rapid Generation of Assay-ready Serial Dilution Plates Using Two-stage Low Volume Pipetting

Jul 22

Researchers see the benefits of streamlining accurate serial dilution of stock solutions of compounds. By Joby Jenkins, TTP LabTech As the cost of drug development escalates there is a growing requirement to accelerate the R&D cycle and eliminate unwanted off-target drug effects earlier.

The Future of the FDA: Operating in an Electronic World

Oct 12

Acording to an Axendia reseach study, the FDA is currently shifting its organizational and technology infrastructures to facilitate electronic interactions with the companies it regulates.

Tissue Microarrays - Opening up new opportunities in the Therapeutics sector

Oct 12

Tissue Microarray has become a pivotal cog in the wheel for high throughput studies and is an integral part in the validation process for screening results from discovery platforms for expression studies using various approaches.

Translational Informatics for Systems Biology

Oct 12

A study in which IO Informatics' Sentient software has been applied to integrating and linking a customer's multiple data streams.

De Novo Formula Generation with Sub-ppm Confidence

Oct 12

Novel technology embodied in the micrOTOF allows precise measurement of both accurate mass and True Isotopic Pattern (TIP) over a wide dynamic range, allowing for the implementation of an open access system.

ADP-Glo™: An Ideal Approach to Monitor the Activity of Protein Kinases and Beyond

Oct 16

Because of its versatility (alltypesofsubstrates), robustness (Z’>0.8), rapidperformance, and its ease of use, the luminescence based Kinase Glo® assay platform has gained wide acceptance in many drug screening programs for protein kinase inhibitors.

A Cell-Based, Microplate Format, DELFIA Assay for Determination of the Activation of MAP KinaseSofia

Oct 16

Mitogen-activated protein kinases(MAPK) are activated in response to extracellularsignals or cellular stress. We have set up a cell-based DELFIA®Time-Resolved Fluorescence assay to test compounds or conditions for their ability to modulate cellular stress by the activation of MAPK.

Cell Based Assays for Studying the Effects of Cytotoxic Agents

Oct 16

Apoptosis, DNA fragmentation and cell proliferation are important parameters when studying live cell function, especially, when the effects of cytotoxic agents are under study.

Input normalization by global feedforward inhibition expands cortical dynamic range

2 hours ago

The cortex is sensitive to weak stimuli, but responds to stronger inputs without saturating. The mechanisms that enable this wide range of operation are not fully understood. We found that the amplitude of excitatory synaptic currents necessary to fire rodent pyramidal cells,...

A genetic pathway composed of Sox14 and Mical governs severing of dendrites during pruning

2 hours ago

Pruning that selectively eliminates neuronal processes is crucial for the refinement of neural circuits during development. In Drosophila, the class IV dendritic arborization neuron (ddaC) undergoes pruning to remove its larval dendrites during metamorphosis. We identified Sox14...

Adult generation of glutamatergic olfactory bulb interneurons

2 hours ago

The adult mouse subependymal zone (SEZ) harbors neural stem cells that are thought to exclusively generate GABAergic interneurons of the olfactory bulb. We examined the adult generation of glutamatergic juxtaglomerular neurons, which had dendritic arborizations that projected...

The pathways of interoceptive awareness

2 hours ago

A network of cortical brain regions, including the insula and anterior cingulate cortex (ACC), has been proposed as the critical and sole substrate for interoceptive awareness. Combining lesion and pharmacological approaches in humans, we found that the insula and ACC were not...

Request for Entries

Oct 16

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Frontiers in Bioscience Learning and Memory Video

Oct 6

How does the brain learn and remember? An academic conference "Frontiers in Bioscience Learning and Memory" was held at City University of Hong Kong on June 16th.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.